| FORM | 4 |
|------|---|
|------|---|

|                       | 1 |
|-----------------------|---|
| Check this box if no  | Ī |
| longer subject to     |   |
| Section 16. Form 4 or |   |
| Form 5 obligations    |   |
| may continue. See     |   |
| Instruction 1(b).     |   |

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

SEC 1474 (9-02)

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| (Print or Type Responses)  |   |                          |  |                            |                  |   |  |       |                         |  |  |  |
|--|---|--------------------------|--|----------------------------|------------------|---|--|-------|-------------------------|--|--|--|
| 1. Name and Address of Rep<br>Scibetta James S   | 2. Issuer Name <b>and</b> Ticker or Trading Symbol<br>Matinas BioPharma Holdings, Inc. [MTNB] |                          |  |                            |                  |   | 5. Relationship of Reporting Person(s) to Issuer<br>(Check all applicable)<br>X Director 10% Owner |       |                         |  |  |  |
| (Last) (Fir<br>C/O MATINAS BIOPH<br>INC., 1545 ROUTE 20                                  | HARMA   | HOLDINGS,                | 3. Date of Earliest 7<br>03/31/2019  | Officer (give title below) | Other (specify b | pelow)  |  |       |                         |  |  |  |
| (Str<br>BEDMINSTER, NJ 07  | 4. If Amendment, I  | Date Origin              | al Fil   | led(Month/D                | ay/Year)         | 6. Individual or Joint/Group Filing(Check Applicable Line)<br>_X_Form filed by One Reporting Person<br>Form filed by More than One Reporting Person |  |       |                         |  |  |  |
| (City) (Sta  | ate)  | (Zip)                    | Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned |                            |                  |   |  |       |                         |  |  |  |
| 1. Title of Security     2. Transaction       (Instr. 3)     Date       (Month/Day/Year) |   | Date<br>(Month/Day/Year) | •  | Code<br>(Instr. 8)         | tion             | 4. Securities Acquired<br>(A) or Disposed of (D)<br>(Instr. 3, 4 and 5)   |  |       | Reported Transaction(s) | Form:  | 7. Nature<br>of Indirect<br>Beneficial |  |
|  |   |                          | (Month/Day/Year)   | Code                       | v                | Amount  | (A)<br>or<br>(D)   | Price | (Instr. 3 and 4)        | Direct (D)<br>or Indirect<br>(I)<br>(Instr. 4) | Ownership<br>(Instr. 4)                |  |
| Common Stock   |   | 03/31/2019               |  | А                          |                  | 17,202<br>(1)   | А  | \$ 0  | 555,280                 | D  |  |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

|             | (e.g., puts, calls, warrants, options, convertible securities) |                  |                    |            |    |            |        |              |                    |        |         |             |                |             |             |
|-------------|--|------------------|--------------------|------------|----|------------|--------|--------------|--------------------|--------|---------|-------------|----------------|-------------|-------------|
| 1. Title of | 2.   | 3. Transaction   | 3A. Deemed         | 4.         |    | 5.         |        | 6. Date Exer | cisable            | 7. Tit | le and  | 8. Price of | 9. Number of   | 10.         | 11. Nature  |
| Derivative  | Conversion   | Date             | Execution Date, if | Transacti  | on | Numł       | ber    | and Expirati | on Date            | Amou   | unt of  | Derivative  | Derivative     | Ownership   | of Indirect |
| Security    | or Exercise  | (Month/Day/Year) | any                | Code       |    | of         |        | (Month/Day   | /Year)             | Unde   | rlying  | Security    | Securities     | Form of     | Beneficial  |
| (Instr. 3)  | Price of   |                  | (Month/Day/Year)   | (Instr. 8) |    | Deriv      | ative  |              |                    | Secur  | rities  | (Instr. 5)  | Beneficially   | Derivative  | Ownership   |
|             | Derivative   |                  |                    |            |    | Secur      | rities |              |                    | (Instr | . 3 and |             | Owned          | Security:   | (Instr. 4)  |
|             | Security   |                  |                    |            |    | Acqu       | ired   |              |                    | 4)     |         |             | Following      | Direct (D)  |             |
|             |  |                  |                    |            |    | (A) o      | r      |              |                    |        |         |             | Reported       | or Indirect |             |
|             |  |                  |                    |            |    | Dispo      | osed   |              |                    |        |         |             | Transaction(s) | (I)         |             |
|             |  |                  |                    |            |    | of (D)     |        |              |                    |        |         | (Instr. 4)  | (Instr. 4)     |             |             |
|             |  |                  |                    |            |    | (Instr. 3, |        |              |                    |        |         |             |                |             |             |
|             |  |                  |                    |            |    | 4, and 5)  |        |              |                    |        |         |             |                |             |             |
|             |  |                  |                    |            |    |            |        |              |                    |        | Amount  |             |                |             |             |
|             |  |                  |                    |            |    |            |        | Date         | Expiration         |        | or      |             |                |             |             |
|             |  |                  |                    |            |    |            |        | Exercisable  | Expiration<br>Date | Title  | Number  |             |                |             |             |
|             |  |                  |                    |            |    |            |        | LACICISADIC  | Date               |        | of      |             |                |             |             |
|             |  |                  |                    | Code       | V  | (A)        | (D)    |              |                    |        | Shares  |             |                |             |             |

## **Reporting Owners**

|   | Relationships |              |         |       |  |  |  |
|---|---------------|--------------|---------|-------|--|--|--|
| Reporting Owner Name / Address  | Director      | 10%<br>Owner | Officer | Other |  |  |  |
| Scibetta James S<br>C/O MATINAS BIOPHARMA HOLDINGS, INC.<br>1545 ROUTE 206 SOUTH, SUITE 302<br>BEDMINSTER, NJ 07921 | Х             |              |         |       |  |  |  |

### **Signatures**

 /s/ Jerome D. Jabbour, attorney-in fact for James S. Scibetta
 04/03/2019

 \*\*Signature of Reporting Person
 Date

# **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) On March 31, 2019, the Reporting Person was issued 17,202 shares of common stock par value \$.0001 per share pursuant to the Company's 2013 Equity Compensation Plan. Such shares vest immediately upon grant.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.